A phenomenon largely ignored since its discovery 100 years ago appears to be a crucial component of diabetic pain, according ...

Publication of the Nalu Real-World Data (RWD) paper in the Chronic Pain and Management Journal is a significant milestone, ...

Detailed analysis reveals what real users are saying about Arialief’s neuropathy relief formula in 2025 - highlighting its ...

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with ...

Publication of the Nalu Real-World Data (RWD) paper in the Chronic Pain and Management Journal is a significant milestone, establishing Nalu peripheral nerve stimulation (PNS) as a medically ...

Q1 2025 Management View Mike Exton, Chief Executive Officer, highlighted a pivotal exclusive license agreement with Novo Nordisk for LX9851, stating "this agreement grants Novo an exclusive worldwide ...

A phenomenon largely ignored since its discovery 100 years ago appears to be a crucial component of diabetic pain, according to new research from The ...

Scientists discovered a hidden CB₁ receptor pocket and engineered a drug to exploit it, offering promise of safer, more ...

Peripheral Neuropathic Pain Plans for Phase 2a Trial in Diabetic Peripheral Neuropathic Pain (DPNP) Being Finalized. An update on the timeline for initiation of the trial in DPNP is expected in 2025.

Findings from a new study show that exercise helps reduce side-effects of cancer treatment such as nausea, ...